These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 15451429)
1. Pharmacological activity of DTPA linked to protein-based drug carrier systems. Michaelis M; Langer K; Arnold S; Doerr HW; Kreuter J; Cinatl J Biochem Biophys Res Commun; 2004 Oct; 323(4):1236-40. PubMed ID: 15451429 [TBL] [Abstract][Full Text] [Related]
2. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Ulbrich K; Michaelis M; Rothweiler F; Knobloch T; Sithisarn P; Cinatl J; Kreuter J Int J Pharm; 2011 Mar; 406(1-2):128-34. PubMed ID: 21185364 [TBL] [Abstract][Full Text] [Related]
3. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065 [TBL] [Abstract][Full Text] [Related]
4. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate. Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211 [TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activities of four chelating agents against human neuroblastoma cells. Shen L; Zhao HY; Du J; Wang F In Vivo; 2005; 19(1):233-6. PubMed ID: 15796180 [TBL] [Abstract][Full Text] [Related]
6. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904 [TBL] [Abstract][Full Text] [Related]
7. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Acharya S; Dilnawaz F; Sahoo SK Biomaterials; 2009 Oct; 30(29):5737-50. PubMed ID: 19631377 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
9. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. Azarmi S; Huang Y; Chen H; McQuarrie S; Abrams D; Roa W; Finlay WH; Miller GG; Löbenberg R J Pharm Pharm Sci; 2006; 9(1):124-32. PubMed ID: 16849014 [TBL] [Abstract][Full Text] [Related]
10. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684 [TBL] [Abstract][Full Text] [Related]
12. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Kohler N; Sun C; Wang J; Zhang M Langmuir; 2005 Sep; 21(19):8858-64. PubMed ID: 16142971 [TBL] [Abstract][Full Text] [Related]
13. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Blaheta RA; Michaelis M; Natsheh I; Hasenberg C; Weich E; Relja B; Jonas D; Doerr HW; Cinatl J Br J Cancer; 2007 Jun; 96(11):1699-706. PubMed ID: 17505515 [TBL] [Abstract][Full Text] [Related]
14. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells. Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655 [TBL] [Abstract][Full Text] [Related]
15. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Menendez JA; Lupu R Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825 [TBL] [Abstract][Full Text] [Related]
16. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167 [TBL] [Abstract][Full Text] [Related]
17. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin. Di Stefano G; Fiume L; Baglioni M; Busi C; Chieco P; Kratz F; Mattioli A Eur J Pharm Sci; 2007 Feb; 30(2):136-42. PubMed ID: 17218086 [TBL] [Abstract][Full Text] [Related]
18. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173 [TBL] [Abstract][Full Text] [Related]
19. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. Akbas SH; Timur M; Ozben T J Surg Res; 2005 May; 125(1):49-55. PubMed ID: 15836850 [TBL] [Abstract][Full Text] [Related]
20. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Menendez JA; Oza BP; Colomer R; Lupu R Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]